Company: MDCXW
Filing Date: 2025-04-04
Form Type: POS AM
Source: 0001062993-25-007073
Chunk: 23

Company: Medicus Pharma Ltd.
Filing Date: 2025-04-04
Form: POS AM
Chunk 23
---
 or results of operations. To the extent that new or improved pharmaceutical drug treatments are introduced that demonstrate better long-term efficacy and safety, patients and physicians may further delay the introduction of patches, such as the Product, if approved, in the skin cancer treatment continuum. the Product could also face competition from other formulations or devices that deliver chemotherapeutic agents on an extended basis.

Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staffs and experienced commercial and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in competitors. As a result, these companies may obtain regulatory approval more rapidly than us are able and may be more effective in selling and marketing their products as well. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis drug products or drug delivery technologies that are more effective or less costly than the Product.

<div align='center'>-14-</div>

We believe that our ability to compete effectively depends upon many factors both within and beyond our control, including:

•the usefulness, ease of use, performance and reliability of our technology compared to our competitors;

•the activity and tolerability of the Product, including relative to marketed products and product candidates in development by third parties;

•the ability to distinguish safety and efficacy from existing, alternative therapies;

•the timing for the Product to complete clinical development and receive market approval;

•acceptance of the Product by patients, physicians and other health providers,

•our ability to monetize our technology;

•the selection of licensing partners for our technology with the necessary skills and resources to drive uptake;

•our marketing and selling efforts;

•our financial condition and results of operations;

•the ability to maintain a good relationship with regulatory authorities;

•the price of our future products, including in comparison to branded or generic competitors;

•whether coverage and adequate levels of reimbursement are available under private and governmental health insurance plans,

•acquisitions or consolidations within our industry, which may result in more formidable competitors;

•our ability to protect our intellectual property rights,

•our ability to attract, retain and motivate talented employees;

•our ability to cost-effectively manage and grow our operations; and

•our reputation and brand strength relative to that of